AGRX Agile Thrpe

USD 1.45 0.01 0.694444
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.45

+0.01 (+0.69)%

USD 9.87M

0.13M

N/A

N/A

Icon

AGRX

Agile Thrpe (USD)
COMMON STOCK | NSD
USD 1.45
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 9.87M

N/A

USD 1.45

Agile Thrpe (AGRX) Stock Forecast

N/A

Based on the Agile Thrpe stock forecast from 0 analysts, the average analyst target price for Agile Thrpe is not available over the next 12 months. Agile Thrpe’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Agile Thrpe is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Agile Thrpe’s stock price was USD 1.45. Agile Thrpe’s stock price has changed by +2.11% over the past week, +326.60% over the past month and -53.23% over the last year.

No recent analyst target price found for Agile Thrpe
No recent average analyst rating found for Agile Thrpe

Company Overview Agile Thrpe

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The co...Read More

500 College Road East, Princeton, NJ, United States, 08540

19

December

USD

USA

Adjusted Closing Price for Agile Thrpe (AGRX)

Loading...

Unadjusted Closing Price for Agile Thrpe (AGRX)

Loading...

Share Trading Volume for Agile Thrpe Shares

Loading...

Compare Performance of Agile Thrpe Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AGRX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Agile Thrpe (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX
Neurocrine Biosciences Inc -0.51 (-0.35%) USD14.84B 39.95 36.15

ETFs Containing AGRX

Symbol Name AGRX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Agile Thrpe (AGRX) Stock

Stock Target Advisor's fundamental analysis for Agile Thrpe's stock is Slightly Bearish.

Unfortunately we do not have enough data on AGRX's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AGRX's stock to indicate what its average analyst target is.

AGRX stock's Price/Earning ratio is 0.05. Our analysis grades AGRX stock's Price / Earning ratio at A-. This means that AGRX stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this AGRX may be undervalued for its sector.

The last closing price of AGRX's stock was USD 1.45.

The most recent market capitalization for AGRX is USD 9.87M.

Unfortunately we do not have enough analyst data on AGRX's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Agile Thrpe's stock.

As per our most recent records Agile Thrpe has 19 Employees.

Agile Thrpe's registered address is 500 College Road East, Princeton, NJ, United States, 08540. You can get more information about it from Agile Thrpe's website at https://www.agiletherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...